These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 27002425)

  • 1. A 50 bp deletion in the SOD1 promoter lowers enzyme expression but is not associated with ALS in Sweden.
    Ingre C; Wuolikainen A; Marklund SL; Birve A; Press R; Andersen PM
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(5-6):452-7. PubMed ID: 27002425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the 50 bp deletion polymorphism in the SOD1 promoter on SOD1 mRNA levels in Italian ALS patients.
    Milani P; Gagliardi S; Bongioanni P; Grieco GS; Dezza M; Bianchi M; Cova E; Ceroni M; Cereda C
    J Neurol Sci; 2012 Feb; 313(1-2):75-8. PubMed ID: 22005552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis.
    Broom WJ; Greenway M; Sadri-Vakili G; Russ C; Auwarter KE; Glajch KE; Dupre N; Swingler RJ; Purcell S; Hayward C; Sapp PC; McKenna-Yasek D; Valdmanis PN; Bouchard JP; Meininger V; Hosler BA; Glass JD; Polack M; Rouleau GA; Cha JH; Hardiman O; Brown RH
    Amyotroph Lateral Scler; 2008 Aug; 9(4):229-37. PubMed ID: 18608091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS.
    Hayashi Y; Homma K; Ichijo H
    Adv Biol Regul; 2016 Jan; 60():95-104. PubMed ID: 26563614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis to explain reduced or increased SOD1 enzymatic activity in ALS patients and their relatives.
    Keskin I; Birve A; Berdynski M; Hjertkvist K; Rofougaran R; Nilsson TK; Glass JD; Marklund SL; Andersen PM
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Aug; 18(5-6):457-463. PubMed ID: 28325066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations.
    Millecamps S; Salachas F; Cazeneuve C; Gordon P; Bricka B; Camuzat A; Guillot-Noël L; Russaouen O; Bruneteau G; Pradat PF; Le Forestier N; Vandenberghe N; Danel-Brunaud V; Guy N; Thauvin-Robinet C; Lacomblez L; Couratier P; Hannequin D; Seilhean D; Le Ber I; Corcia P; Camu W; Brice A; Rouleau G; LeGuern E; Meininger V
    J Med Genet; 2010 Aug; 47(8):554-60. PubMed ID: 20577002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kaplan-Meier Meets Chemical Kinetics: Intrinsic Rate of SOD1 Amyloidogenesis Decreased by Subset of ALS Mutations and Cannot Fully Explain Age of Disease Onset.
    Abdolvahabi A; Shi Y; Rasouli S; Croom CM; Aliyan A; Martí AA; Shaw BF
    ACS Chem Neurosci; 2017 Jun; 8(6):1378-1389. PubMed ID: 28290665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for progression in amyotrophic lateral sclerosis associated to SOD1 mutation: insight from two population-based registries.
    Martinelli I; Ghezzi A; Zucchi E; Gianferrari G; Ferri L; Moglia C; Manera U; Solero L; Vasta R; Canosa A; Grassano M; Brunetti M; Mazzini L; De Marchi F; Simonini C; Fini N; Vinceti M; Pinti M; Chiò A; Calvo A; Mandrioli J
    J Neurol; 2023 Dec; 270(12):6081-6092. PubMed ID: 37668704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspective on SOD1 mediated toxicity in Amyotrophic Lateral Sclerosis.
    Sangwan S; Eisenberg DS
    Postepy Biochem; 2016; 62(3):362-369. PubMed ID: 28132491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?
    Felbecker A; Camu W; Valdmanis PN; Sperfeld AD; Waibel S; Steinbach P; Rouleau GA; Ludolph AC; Andersen PM
    J Neurol Neurosurg Psychiatry; 2010 May; 81(5):572-7. PubMed ID: 20460594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients.
    Zetterström P; Andersen PM; Brännström T; Marklund SL
    J Neurochem; 2011 Apr; 117(1):91-9. PubMed ID: 21226712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human SOD1 ALS Mutations in a Drosophila Knock-In Model Cause Severe Phenotypes and Reveal Dosage-Sensitive Gain- and Loss-of-Function Components.
    Şahin A; Held A; Bredvik K; Major P; Achilli TM; Kerson AG; Wharton K; Stilwell G; Reenan R
    Genetics; 2017 Feb; 205(2):707-723. PubMed ID: 27974499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p.E22G mutation in the Cu/Zn superoxide-dismutase gene predicts a long survival time: clinical and genetic characterization of a seven-generation ALS1 Spanish pedigree.
    Syriani E; Morales M; Gamez J
    J Neurol Sci; 2009 Oct; 285(1-2):46-53. PubMed ID: 19524271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS.
    Synofzik M; Ronchi D; Keskin I; Basak AN; Wilhelm C; Gobbi C; Birve A; Biskup S; Zecca C; Fernández-Santiago R; Kaugesaar T; Schöls L; Marklund SL; Andersen PM
    Hum Mol Genet; 2012 Aug; 21(16):3568-74. PubMed ID: 22595972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration.
    Opie-Martin S; Iacoangeli A; Topp SD; Abel O; Mayl K; Mehta PR; Shatunov A; Fogh I; Bowles H; Limbachiya N; Spargo TP; Al-Khleifat A; Williams KL; Jockel-Balsarotti J; Bali T; Self W; Henden L; Nicholson GA; Ticozzi N; McKenna-Yasek D; Tang L; Shaw PJ; Chio A; Ludolph A; Weishaupt JH; Landers JE; Glass JD; Mora JS; Robberecht W; Damme PV; McLaughlin R; Hardiman O; van den Berg L; Veldink JH; Corcia P; Stevic Z; Siddique N; Silani V; Blair IP; Fan DS; Esselin F; de la Cruz E; Camu W; Basak NA; Siddique T; Miller T; Brown RH; Al-Chalabi A; Shaw CE
    Nat Commun; 2022 Nov; 13(1):6901. PubMed ID: 36371497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1?
    Gamez J; Corbera-Bellalta M; Nogales G; Raguer N; García-Arumí E; Badia-Canto M; Lladó-Carbó E; Alvarez-Sabín J
    J Neurol Sci; 2006 Aug; 247(1):21-8. PubMed ID: 16674979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gibbs Energy of Superoxide Dismutase Heterodimerization Accounts for Variable Survival in Amyotrophic Lateral Sclerosis.
    Shi Y; Acerson MJ; Abdolvahabi A; Mowery RA; Shaw BF
    J Am Chem Soc; 2016 Apr; 138(16):5351-62. PubMed ID: 27054659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants in candidate ALS modifier genes linked to Cu/Zn superoxide dismutase do not explain divergent survival phenotypes.
    Broom WJ; Russ C; Sapp PC; McKenna-Yasek D; Hosler BA; Andersen PM; Brown RH
    Neurosci Lett; 2006 Jan; 392(1-2):52-7. PubMed ID: 16174551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HFE p.H63D polymorphism does not influence ALS phenotype and survival.
    Chiò A; Mora G; Sabatelli M; Caponnetto C; Lunetta C; Traynor BJ; Johnson JO; Nalls MA; Calvo A; Moglia C; Borghero G; Monsurrò MR; La Bella V; Volanti P; Simone I; Salvi F; Logullo FO; Nilo R; Giannini F; Mandrioli J; Tanel R; Murru MR; Mandich P; Zollino M; Conforti FL; Penco S; ; ; Brunetti M; Barberis M; Restagno G
    Neurobiol Aging; 2015 Oct; 36(10):2906.e7-11. PubMed ID: 26174855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA sequence analysis of the conserved region around the SOD1 gene locus in recessively inherited ALS.
    Broom WJ; Johnson DV; Garber M; Andersen PM; Lennon N; Landers J; Nusbaum C; Russ C; Brown RH
    Neurosci Lett; 2009 Sep; 463(1):64-9. PubMed ID: 19596401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.